Evidence map›Paper›PMID 40970963›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

[

Congcong Yu, Jing Wang, Lin Chen, Rui Zhou, Xiaofeng Dou, Mei Tian, Hong Zhang, Xiaohui Zhang, Chentao Jin

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Congcong Yu *Department of Nuclear Medicine and Medical PET Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Jing Wang *Department of Nuclear Medicine and Medical PET Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Lin Chen *Department of Nuclear Medicine and Medical PET Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Rui ZhouDepartment of Nuclear Medicine and Medical PET Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Xiaofeng DouDepartment of Nuclear Medicine and Medical PET Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Mei TianHuman Phenome Institute, Fudan University, Shanghai, China. tianmei@fudan.edu.cn.
Hong ZhangDepartment of Nuclear Medicine and Medical PET Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. hzhang21@zju.edu.cn.ORCID 0000-0002-4084-5150
Xiaohui ZhangDepartment of Nuclear Medicine and Medical PET Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. zhanghui4127@zju.edu.cn.
Chentao JinDepartment of Nuclear Medicine and Medical PET Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. chentao_jin@zju.edu.cn.

Funding

Fundamental Research Funds for the Central Universities 226-2024-00059Key Technologies Research and Development Program 2021YFA1101700, 2022YFE0118000National Natural Science Foundation of China 82030049National Natural Science Foundation of China 82372025
6 · The paper itself

Abstract

purposeTo investigate the prognostic values of 2-deoxy-2-[ MATERIALS AND

methodsThirty-nine patients who received Pola-containing regimens and underwent pre-treatment [

resultsThe median follow-up duration was 17.2 months (range 3.28 months - 26.2 months). During this period, 16 patients (41.0%) experienced progression. Patients with complete metabolic responses (CMR) exhibited superior outcomes than patients with partial metabolic responses (PMR). ROC and Cox analysis demonstrated that MTV and TLG based on SUV 4.0 segmentation showed superior predictive performance than those based on the 41% SUVmax method. Multivariate Cox regression analysis identified SUVmean (P = 0.016, HR = 1.27) and MTV (P = 0.002, HR = 1.01) on first follow-up PET as independent predictors of progression-free survival (PFS).

conclusionCMR patients exhibited superior outcomes than PMR patients, and SUVmean and MTV on the first follow-up PET were independent predictors of PFS, suggesting that [

Indexed as

Fluorodeoxyglucose F18ImmunoconjugatesLymphoma, Large B-Cell, DiffusePositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overAntibodies, MonoclonalFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesTreatment OutcomeAntibodies, MonoclonalFluorodeoxyglucose F18Immunoconjugatespolatuzumab vedotin[18F]FDG PET/CTDiffuse large b-cell lymphomaPolatuzumab vedotinPrognosis

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.